Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 8, 2012, Pages 797-802

  Koh, Won Jung ^a   Jeong, Byeong Ho ^a   Jeon, Kyeongman ^a   Lee, Soo Youn ^a   Shin, Sung Jae ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Clarithromycin; Drug monitoring; Mycobacterium avium complex; Nontuberculous mycobacteria; Treatment outcome

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; RIFABUTIN; RIFAMPICIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; ANTIBIOTICS, ANTITUBERCULAR; CLARITHROMYCIN; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; ETHAMBUTOL; FEMALE; HUMANS; LOGISTIC MODELS; LUNG DISEASES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RIFABUTIN; RIFAMPIN;

EID: 84867621188     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201206-1088OC     Document Type: Article

References (33)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
2. Daley CL, Griffith DE. Pulmonary non-tuberculous mycobacterial infections. Int J Tuberc Lung Dis 2010;14:665-671.
3. Prevots DR, Shaw PA, Strickland D, Jackson LA, Raebel MA, Blosky MA, Montes de Oca R, Shea YR, Seitz AE, Holland SM, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010;182:970-976.
4. Adjemian J, Olivier KN, Seitz AE, Holland SM, Prevots DR. Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries. Am J Respir Crit Care Med 2012;185:881-886.
5. Field SK, Fisher D, Cowie RL. Mycobacterium avium complex pulmonary disease in patients without HIV infection. Chest 2004;126:566-581. (Pubitemid 39093445)
6. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289. (Pubitemid 43848401)
7. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 2007;101:130-138. (Pubitemid 44835234)
8. Koh WJ, Jeong BH, Jeon K, Lee NY, Lee KS, Woo SY, Shin SJ, Kwon OJ. Clinical significance of the differentiation between Mycobacterium avium and Mycobacterium intracellulare in M. avium complex lung disease. Chest (In press)
9. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995;171:747-750.
10. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.
11. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186:559-565.
12. Peloquin CA. Mycobacterium avium complex infection: pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes. Clin Pharmacokinet 1997;32:132-144. (Pubitemid 27104412)
13. Gilljam M, Berning SE, Peloquin CA, Strandvik B, Larsson LO. Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease. Eur Respir J 1999;14:347-351. (Pubitemid 29461300)
14. Jeon K, Kwon OJ, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Koh WJ. Antibiotic treatment of Mycobacterium abscessus lung disease: a retrospective analysis of 65 patients. Am J Respir Crit Care Med 2009;180:896-902.
15. Koh WJ, Jeon K, Lee NY, Kim BJ, Kook YH, Lee SH, Park YK, Kim CK, Shin SJ, Huitt GA, et al. Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus. Am J Respir Crit Care Med 2011;183:405-410.
16. Clinical and Laboratory Standards Institute (CLSI). Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard-second edition, Document no. M24-A2. Wayne, PA: CLSI; 2011.
17. Peloquin CA. Using therapeutic drug monitoring to dose the antimycobacterial drugs. Clin Chest Med 1997;18:79-87. (Pubitemid 27152505)
18. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002;62:2169-2183. (Pubitemid 35252827)
19. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010;16:1546-1553.
20. Magis-Escurra C, van den Boogaard J, Ijdema D, BoereeM, Aarnoutse R. Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 2012;25:83-86.
21. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998;113:1178-1183. (Pubitemid 28223801)
22. Mehta JB, Shantaveerapa H, Byrd RP Jr, Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001;120:1520-1524. (Pubitemid 33078467)
23. Nuermberger E, Grosset J. Pharmacokinetic and pharmacodynamic issues in the treatment of mycobacterial infections. Eur J Clin Microbiol Infect Dis 2004;23:243-255. (Pubitemid 38669936)
24. Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. Antimicrob Agents Chemother 1988;32:1131-1136.
25. Zuckerman JM, Qamar F, Bono BR. Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 2011;95:761-791.
26. Hasegawa N, Nishimura T, Watabnabe M, Tasaka S, Nakano Y, Yamazaki K, Hashimoto S, Nishimura M, Ishizaka A. Concentrations of clarithromycin and active metabolite in the epithelial lining fluid of patients with Mycobacterium avium complex pulmonary disease. Pulm Pharmacol Ther 2009;22:190-193.
27. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan-including a follow-up study. Respiration 2007;74:394-400. (Pubitemid 47093151)
28. Hasegawa N, Nishimura T, Ohtani S, Takeshita K, Fukunaga K, Tasaka S, Urano T, Ishii K, Miyairi M, Ishizaka A. Therapeutic effects of various initial combinations of chemotherapy including clarithromycin against Mycobacterium avium complex pulmonary disease. Chest 2009;136:1569-1575.
29. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease. J Infect (In press)
30. Kim EY, Chi SY, Oh IJ, Kim KS, Kim YI, Lim SC, Kim YC, Kwon YS. Treatment outcome of combination therapy including clarithromycin for Mycobacterium avium complex pulmonary disease. Korean J Intern Med 2011;26:54-59.
31. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012;18:436-443.
32. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-221. (Pubitemid 23107304)
33. Yew WW. Therapeutic drug monitoring in antituberculosis chemotherapy. Ther Drug Monit 1998;20:469-472. (Pubitemid 28463434)